📊 BSPK Key Takeaways
Is Bespoke Extracts, Inc. (BSPK) a Good Investment?
Bespoke Extracts is in severe financial distress with negative stockholders' equity of -$2.6M, indicating liabilities exceed assets by a significant margin. Despite 42.3% revenue growth, the company is deeply unprofitable with a -48.5% net margin, burning cash at an alarming rate (-$723.6K free cash flow) while maintaining minimal liquidity (0.11x current ratio). The combination of deteriorating financial position, negative equity, and unsustainable cash burn presents an extreme capital structure risk.
Bespoke Extracts shows real top-line growth and a respectable gross margin, but the business remains deeply unprofitable with sharply worsening net losses relative to its small revenue base. Financial health is extremely weak: negative equity, severe working-capital strain, minimal cash, and heavily negative free cash flow all indicate that the current growth profile is not yet translating into sustainable operating performance.
Why Buy Bespoke Extracts, Inc. Stock? BSPK Key Strengths
- Revenue growth of 42.3% year-over-year demonstrates market traction
- Gross margin of 48.4% suggests underlying product economics are viable
- Some improvement in diluted EPS despite continued losses
- Revenue grew 42.3% YoY, indicating some commercial traction
- Gross margin of 48.4% suggests the core product mix can generate meaningful gross profit
- Operating cash burn is smaller than net loss, which may indicate some non-cash expense support
BSPK Stock Risks: Bespoke Extracts, Inc. Investment Risks
- Negative stockholders' equity of -$2.6M indicates insolvency risk and potential total loss for equity holders
- Critically low liquidity ratios (0.11x current ratio, 0.07x quick ratio) with only $16.7K cash against $2.9M liabilities
- Severe cash burn with -$123.6K operating cash flow and -$723.6K free cash flow unsustainable without immediate capital injection
- Operating margin of -41.1% with $461.2K operating loss shows inability to scale profitably
- High capex of $600K relative to $1.1M revenue suggests investment-phase company without path to profitability
- Current ratio of 0.11x and cash of only $16.74K point to acute liquidity risk
- Negative stockholders' equity of $-2.60M reflects a highly stressed balance sheet
- Net margin of -48.5% and free cash flow of -$723.56K show growth is currently low quality and not self-funding
Key Metrics to Watch
- Stockholders' equity trajectory - critical threshold is returning to positive territory
- Operating cash flow - must stabilize and turn positive within 1-2 quarters
- Gross margin sustainability - watch for pricing pressure or cost inflation
- Burn rate relative to cash runway - current trajectory suggests imminent liquidity crisis
- Quarterly operating cash flow and ending cash balance
- Operating margin improvement relative to revenue growth
Bespoke Extracts, Inc. (BSPK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BSPK Profit Margin, ROE & Profitability Analysis
BSPK vs Healthcare Sector: How Bespoke Extracts, Inc. Compares
How Bespoke Extracts, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bespoke Extracts, Inc. Stock Overvalued? BSPK Valuation Analysis 2026
Based on fundamental analysis, Bespoke Extracts, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bespoke Extracts, Inc. Balance Sheet: BSPK Debt, Cash & Liquidity
BSPK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bespoke Extracts, Inc.'s revenue has grown significantly by 6,920% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.15 indicates the company is currently unprofitable.
BSPK Revenue Growth, EPS Growth & YoY Performance
BSPK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $277.5K | -$78.1K | $-0.01 |
| Q2 2025 | $278.2K | -$205.1K | $-0.02 |
| Q1 2025 | $260.4K | -$260.5K | $-0.02 |
| Q3 2024 | $244.4K | -$275.6K | $-0.03 |
| Q2 2024 | $188.2K | -$260.9K | $-0.03 |
| Q1 2024 | $89.0K | -$314.1K | $-0.03 |
| Q3 2023 | $3.4K | -$301.5K | $-0.01 |
| Q2 2023 | $346 | -$464.9K | $-0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bespoke Extracts, Inc. Dividends, Buybacks & Capital Allocation
BSPK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bespoke Extracts, Inc. (CIK: 0001409197)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BSPK
What is the AI rating for BSPK?
Bespoke Extracts, Inc. (BSPK) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 95% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BSPK's key strengths?
Claude: Revenue growth of 42.3% year-over-year demonstrates market traction. Gross margin of 48.4% suggests underlying product economics are viable. ChatGPT: Revenue grew 42.3% YoY, indicating some commercial traction. Gross margin of 48.4% suggests the core product mix can generate meaningful gross profit.
What are the risks of investing in BSPK?
Claude: Negative stockholders' equity of -$2.6M indicates insolvency risk and potential total loss for equity holders. Critically low liquidity ratios (0.11x current ratio, 0.07x quick ratio) with only $16.7K cash against $2.9M liabilities. ChatGPT: Current ratio of 0.11x and cash of only $16.74K point to acute liquidity risk. Negative stockholders' equity of $-2.60M reflects a highly stressed balance sheet.
What is BSPK's revenue and growth?
Bespoke Extracts, Inc. reported revenue of $1.1M.
Does BSPK pay dividends?
Bespoke Extracts, Inc. does not currently pay dividends.
Where can I find BSPK SEC filings?
Official SEC filings for Bespoke Extracts, Inc. (CIK: 0001409197) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BSPK's EPS?
Bespoke Extracts, Inc. has a diluted EPS of $-0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BSPK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bespoke Extracts, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BSPK stock overvalued or undervalued?
Valuation metrics for BSPK: ROE of N/A (sector avg: 15%), net margin of -48.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BSPK stock in 2026?
Our dual AI analysis gives Bespoke Extracts, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BSPK's free cash flow?
Bespoke Extracts, Inc.'s operating cash flow is $-123.6K, with capital expenditures of $600.0K. FCF margin is -64.5%.
How does BSPK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -48.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.11 (avg: 2).